Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5441402 | 0.99 | F10 (1.00) | F10KLKB1NPC1RAB9A | |
| SCHEMBL9976455 | 0.90 | F10 (1.00) | F10KLKB1NPC1RAB9A | |
| SCHEMBL5399426 | 0.89 | F10 (1.00) | F10KLKB1 | |
| SCHEMBL9928647 | 0.89 | F10 (0.84) | F10KLKB1 | |
| SCHEMBL5409814 | 0.89 | F10 (0.84) | F10KLKB1 | |
| SCHEMBL9979748 | 0.87 | F10 (0.77) | F10KLKB1 | |
| Darexaban SCHEMBL2227024 | 0.87 | F10 (1.00) | F10KLKB1 | |
| SCHEMBL2230035 | 0.87 | F10 (1.00) | F10KLKB1 | |
| SCHEMBL5398111 | 0.87 | F10 (1.00) | F10KLKB1NPC1RAB9A | |
| SCHEMBL5401508 | 0.84 | F10 (0.81) | F10KLKB1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | claimed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | claimed |
| EP-1415990-B1 | Diazepan derivatives useful as factor X inhibitor | ASTELLAS PHARMA INC (JP) | 2006-09-20 | — | — | EP | claimed |
| EP-1415990-A1 | Diazepan derivatives useful as factor X inhibitor | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | claimed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | claimed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-7307074-B2 | Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration | ASTELLAS PHARMA INC. (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
| EP-1273575-A4 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-01-08 | — | — | EP | disclosed |
| CN-1319594-A | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2001-10-31 | — | — | CN | disclosed |
| WO-2001074791-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195193-A1 | Diazepane derivatives or salts thereof | F10, F11, SERPINC1 | F10 1/4885KLKB1 143/4885NPC1 3193/4885 |
| US-20040068109-A1 | Diazepan derivatives or salts thereof | F10, SERPINC1, F11 | F10 1/4885KLKB1 158/4885NPC1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.